Godin Stephen J, Crow J Allen, Scollon Edward J, Hughes Michael F, DeVito Michael J, Ross Matthew K
United States Environmental Protection Agency, Office of Research and Development, National Health and Environmental Effects Resource Laboratory, Experimental Toxicology Division, Pharmacokinetics Branch, Research Triangle Park, NC 27711, USA.
Drug Metab Dispos. 2007 Sep;35(9):1664-71. doi: 10.1124/dmd.107.015388. Epub 2007 Jun 18.
The metabolism of (alphaS)-cyano-3-phenoxybenzyl (1R, 3R)-cis-3-(2,2-dibromovinyl)-2,2-dimethylcyclopropane carboxylate (deltamethrin) and (alphaS)-cyano-3-phenoxybenzyl 2-(4-chlorophenyl)-3-methylbutyrate (esfenvalerate) by rat and human liver microsomes differs with respect to the biotransformation pathway (oxidation versus hydrolysis) responsible for their clearance. This study aims to further explore the species differences in the metabolism of these chemicals. Using a parent depletion approach, rat and human cytochromes P450 (P450s) were screened for their ability to eliminate deltamethrin or esfenvalerate during in vitro incubations. Rat P450 isoforms CYP1A1, CYP2C6, CYP2C11, and CYP3A2 and human P450 isoforms CYP2C8, CYP2C19, and CYP3A5 were capable of metabolizing either pyrethroid. Human CYP2C9 metabolized esfenvalerate but not deltamethrin. Rat and human P450s that metabolize esfenvalerate and deltamethrin do so with similar kinetics. In addition to the liver, a potential site of metabolic elimination of pyrethroids is the blood via serum carboxylesterase (CE) hydrolysis. The serum of rats, but not humans, contains significant quantities of CE. Deltamethrin and esfenvalerate were metabolized effectively by rat serum and a purified rat serum CE. In contrast, neither pyrethroid was metabolized by human serum or purified human serum esterases (acetylcholinesterase and butyrylcholinesterase). These studies suggest that the difference in rates of oxidative metabolism of pyrethroids by rat and human hepatic microsomes is dependent on the expression levels of individual P450 isoforms rather than their specific activity. Furthermore, these studies show that the metabolic elimination of deltamethrin and esfenvalerate in blood may be important to their disposition in rats but not in humans.
(αS)-氰基-3-苯氧基苄基(1R,3R)-顺式-3-(2,2-二溴乙烯基)-2,2-二甲基环丙烷羧酸酯(溴氰菊酯)和(αS)-氰基-3-苯氧基苄基2-(4-氯苯基)-3-甲基丁酸酯(乙氰菊酯)在大鼠和人肝脏微粒体中的代谢在负责其清除的生物转化途径(氧化与水解)方面存在差异。本研究旨在进一步探究这些化学物质代谢中的种属差异。采用母体药物消耗法,在体外孵育过程中筛选大鼠和人细胞色素P450(P450s)消除溴氰菊酯或乙氰菊酯的能力。大鼠P450同工酶CYP1A1、CYP2C6、CYP2C11和CYP3A2以及人P450同工酶CYP2C8、CYP2C19和CYP3A5能够代谢这两种拟除虫菊酯。人CYP2C9可代谢乙氰菊酯,但不能代谢溴氰菊酯。代谢乙氰菊酯和溴氰菊酯的大鼠和人P450具有相似的动力学特征。除肝脏外,拟除虫菊酯代谢消除的一个潜在部位是通过血清羧酸酯酶(CE)水解的血液。大鼠血清中含有大量CE,而人血清中则没有。溴氰菊酯和乙氰菊酯可被大鼠血清和纯化的大鼠血清CE有效代谢。相比之下,这两种拟除虫菊酯均不能被人血清或纯化的人血清酯酶(乙酰胆碱酯酶和丁酰胆碱酯酶)代谢。这些研究表明,大鼠和人肝脏微粒体对拟除虫菊酯氧化代谢速率的差异取决于各个P450同工酶的表达水平,而非其比活性。此外,这些研究表明,溴氰菊酯和乙氰菊酯在血液中的代谢消除对其在大鼠体内的处置可能很重要,但对人则不然。